MX2020004334A - Receptor de celulas t novedoso. - Google Patents
Receptor de celulas t novedoso.Info
- Publication number
- MX2020004334A MX2020004334A MX2020004334A MX2020004334A MX2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A MX 2020004334 A MX2020004334 A MX 2020004334A
- Authority
- MX
- Mexico
- Prior art keywords
- tcr
- cell
- clone
- vector
- immunogenic
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 11
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717578.7A GB201717578D0 (en) | 2017-10-26 | 2017-10-26 | Novel T-cell receptor |
| GBGB1806155.6A GB201806155D0 (en) | 2017-10-26 | 2018-04-16 | Novel t-cell receptor |
| PCT/GB2018/053045 WO2019081902A1 (en) | 2017-10-26 | 2018-10-22 | NEW LYMPHOCYTE RECEPTOR T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004334A true MX2020004334A (es) | 2020-08-03 |
Family
ID=60580240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004334A MX2020004334A (es) | 2017-10-26 | 2018-10-22 | Receptor de celulas t novedoso. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11725039B2 (enExample) |
| EP (2) | EP4039700A1 (enExample) |
| JP (1) | JP7289311B2 (enExample) |
| KR (1) | KR20200078497A (enExample) |
| CN (1) | CN111278855B (enExample) |
| AU (2) | AU2018356944A1 (enExample) |
| BR (1) | BR112020007880A2 (enExample) |
| CA (1) | CA3077635A1 (enExample) |
| DK (1) | DK3700925T3 (enExample) |
| EA (1) | EA202091015A1 (enExample) |
| ES (1) | ES2907819T3 (enExample) |
| GB (2) | GB201717578D0 (enExample) |
| IL (1) | IL274025A (enExample) |
| MX (1) | MX2020004334A (enExample) |
| PL (1) | PL3700925T3 (enExample) |
| SG (1) | SG11202002537WA (enExample) |
| WO (1) | WO2019081902A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
| JP2023510806A (ja) * | 2020-01-09 | 2023-03-15 | ビオミュネクス・ファーマシューティカルズ | Ｍａｉｔ及び腫瘍細胞の両方に結合する多重特異性抗体 |
| JP7680769B2 (ja) * | 2020-01-16 | 2025-05-21 | ウニヴェルズィテート バーゼル | 免疫調節用のｍｒ１リガンド及び医薬組成物 |
| KR20210153539A (ko) * | 2020-06-10 | 2021-12-17 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
| KR20230096110A (ko) * | 2020-11-04 | 2023-06-29 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양을 표적화하는 멀티플렉스화된 조작 iPSC 및 면역 효과기 세포 |
| WO2022118043A1 (en) | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
| WO2022248881A1 (en) | 2021-05-28 | 2022-12-01 | Enara Bio Limited | Novel protein-ligand complex |
| AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023002204A1 (en) | 2021-07-21 | 2023-01-26 | Enara Bio Limited | T-cell receptor |
| WO2023106894A1 (ko) * | 2021-12-10 | 2023-06-15 | 주식회사 유틸렉스 | Mr1 제한적 panck t 세포 및 이의 제조방법 |
| EP4472742A1 (en) | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636065B (zh) * | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| CN106103711A (zh) * | 2013-11-21 | 2016-11-09 | 组库创世纪株式会社 | T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用 |
| JP7233103B2 (ja) * | 2017-03-07 | 2023-03-06 | ウニヴェルズィテート バーゼル | 癌免疫療法用ｍｒ１制限ｔ細胞受容体 |
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
-
2017
- 2017-10-26 GB GBGB1717578.7A patent/GB201717578D0/en not_active Ceased
-
2018
- 2018-04-16 GB GBGB1806155.6A patent/GB201806155D0/en not_active Ceased
- 2018-10-22 EA EA202091015A patent/EA202091015A1/ru unknown
- 2018-10-22 PL PL18795783T patent/PL3700925T3/pl unknown
- 2018-10-22 ES ES18795783T patent/ES2907819T3/es active Active
- 2018-10-22 CN CN201880069546.9A patent/CN111278855B/zh not_active Expired - Fee Related
- 2018-10-22 EP EP21214567.6A patent/EP4039700A1/en not_active Withdrawn
- 2018-10-22 KR KR1020207011102A patent/KR20200078497A/ko not_active Ceased
- 2018-10-22 SG SG11202002537WA patent/SG11202002537WA/en unknown
- 2018-10-22 AU AU2018356944A patent/AU2018356944A1/en not_active Abandoned
- 2018-10-22 MX MX2020004334A patent/MX2020004334A/es unknown
- 2018-10-22 EP EP18795783.2A patent/EP3700925B8/en active Active
- 2018-10-22 JP JP2020543406A patent/JP7289311B2/ja active Active
- 2018-10-22 CA CA3077635A patent/CA3077635A1/en active Pending
- 2018-10-22 BR BR112020007880-8A patent/BR112020007880A2/pt unknown
- 2018-10-22 WO PCT/GB2018/053045 patent/WO2019081902A1/en not_active Ceased
- 2018-10-22 DK DK18795783.2T patent/DK3700925T3/da active
-
2020
- 2020-04-19 IL IL274025A patent/IL274025A/en unknown
- 2020-04-24 US US16/858,082 patent/US11725039B2/en active Active
-
2021
- 2021-01-20 US US17/153,329 patent/US11078252B2/en active Active
-
2024
- 2024-04-26 AU AU2024202735A patent/AU2024202735A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024202735A1 (en) | 2024-05-30 |
| GB201806155D0 (en) | 2018-05-30 |
| SG11202002537WA (en) | 2020-05-28 |
| PL3700925T3 (pl) | 2022-05-02 |
| US20200369742A1 (en) | 2020-11-26 |
| JP2021500406A (ja) | 2021-01-07 |
| CA3077635A1 (en) | 2019-05-02 |
| EP3700925A1 (en) | 2020-09-02 |
| EP3700925B8 (en) | 2022-02-16 |
| AU2018356944A1 (en) | 2020-04-16 |
| US11725039B2 (en) | 2023-08-15 |
| US20210147506A1 (en) | 2021-05-20 |
| BR112020007880A2 (pt) | 2020-10-27 |
| JP7289311B2 (ja) | 2023-06-09 |
| ES2907819T3 (es) | 2022-04-26 |
| EP4039700A1 (en) | 2022-08-10 |
| CN111278855A (zh) | 2020-06-12 |
| DK3700925T3 (en) | 2022-04-04 |
| CN111278855B (zh) | 2024-04-02 |
| EA202091015A1 (ru) | 2020-07-17 |
| IL274025A (en) | 2020-06-30 |
| KR20200078497A (ko) | 2020-07-01 |
| GB201717578D0 (en) | 2017-12-13 |
| WO2019081902A1 (en) | 2019-05-02 |
| EP3700925B1 (en) | 2021-12-29 |
| US11078252B2 (en) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004334A (es) | Receptor de celulas t novedoso. | |
| PH12019500436A1 (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| CL2017000515A1 (es) | Cd123 agentes enlazadores y su uso | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| ECSP22057324A (es) | Compuesto de piridazinil-tiazolcarboxamida | |
| CO2018005695A2 (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
| MX2018002043A (es) | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. | |
| MX2017015473A (es) | Tratamiento contra el cancer por manipulacion de la microflora comensal. | |
| EP4592391A3 (en) | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| MX377753B (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
| BR112018011622A2 (pt) | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae | |
| UY36961A (es) | Receptores celulares universales programables y métodos para usar los mismos | |
| DOP2017000219A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
| MX2020005200A (es) | Novedoso receptor de celulas t gamma delta y su ligando. | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| MX2016014826A (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MX2019013071A (es) | Metodo de tratamiento inmunoterapeutico de un tumor. | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| MX2020005495A (es) | Anticuerpo anti-vista y uso del mismo. | |
| HK1253098A1 (zh) | 用於治疗癌症的mdm2抑制剂的给药方案 | |
| BR112018014723A2 (pt) | fantasmas bacterianos para o tratamento de câncer |